News

November 2018

 

Galil Ofek wishes to welcome OnePass Medical – the last addition to the portfolio

OnePass Medical

OnePass Medical technology is developing InstaFan™ with 5 needles , which enable the clinician to take 5 samples from 5 different locations in one insertion, reducing procedure time and costs and decreasing false negatives answers.

Endoscopic Ultrasound (EUS) Fine Needle Aspiration (FNA) diagnostic procedure is a clinically proven procedure gaining volume in recent years. When a suspected tumor, for example in the pancreas, is located by the ultrasound equipped endoscope, a one-time-use FNA needle device is used to obtain a sample (biopsy). Research showed that 3 to 7 samples, taken from different points in the suspected tumor, provide a high enough detection rate and low error probability. Therefore, the guidelines instruct physicians to obtain multiple samples by needle re-insertion, called “fanning”. Fanning is challenging since the needle tends to find its way to its previous tract in the tissue, ending up in the same sampling site while the physician is unaware of it.

There are currently several EUS-FNA needles on the market, all are with one needle. OnePass Medical technology equipped InstaFan™ with 5 needles , allows the clinician to take 5 samples from 5 different locations in one insertion, reducing the false negative, procedure time and costs.

 

News from portfolio companies

BioBetter

BioBetter has successfully completed fund-raising to finance the construction of the company’s pilot facility in Kiryat Shmona. The new facility will enable scaling up the process of extraction and purification of the company’s recombinant antibody.

Marpe Medical

Marpe Medical has installed at the Ichilov Medical Center in Tel Aviv the company’s second system. The first system was installed at the Bnei Zion Medical Center in Haifa. The system collects and analyzes clinical data as part of the company ongoing clinical study.

 

August 2018

 

Galil Ofek wishes to welcome the latest additions to our portfolio

IOP Medical

IOP Medical develops an implantable sensor for self-monitoring of intraocular pressure with a simple smartphone camera. Intraocular pressure is the main treatable risk factor for Glaucoma. The company is led by Dr. Yossi Mandel, the inventor and chief scientist, who serves as a senior eye researcher at Bar Ilan University; Nir Sinai, the R&D leader, previously lead Hanita Lenses R&D and other medical eye related projects; Adam Parnes, Chairman, previously served as Head of Oscar Gruss Israel and leader of several successful medical ventures.

InVatin

InVatin develops a device that is implanted in the aortic arch, either for life, or for a limited time span, aiming at reducing the risk of CVA. The technology uses a special filtering and Venturi generating mechanism to direct risky emboli down into the abdominal aorta and lower body parts, preventing them from entering the cerebral blood system. InVatin, was founded by Udi Nussinovitch, MD, PhD.

Welcome
Gideon Meiry is Galil ofek new CTO.
Gideon is a multidisciplinary scientist and entrepreneur with long track records and vast experience in leading multidisciplinary teams, inventing and managing intellectual property, managing R&D from concept to product, executing regulatory and reimbursement strategies, fundraising and marketing. Gideon serves also as a technology transfer advisor to the Galil Medical Center. Gideon holds a PhD degree in Physiology and Biophysics from the Faculty of Medicine, Technion, Israel Institute of Technology.

Koby Cohen is our new CTO Pharma.
Kobi Cohen, Ph.D.
Kobi is a life science professional with extensive experience in drug development, project scouting and evaluation.  Before joining Galil-Ofek, Kobi held a director position at the Global innovative R&D at Teva Pharmaceutical Industries. Kobi was responsible for identifying and pursuing collaborations, licenses and partnerships from biotech companies and academic institutions worldwide. Kobi completed PhD and post doc fellowship at the Tel Aviv University and The Weizmann institute of science.
Thank You!
We would like to thank our former CTO Arnin Cohen, for his excellent contribution to Galil Ofek.

Welcome to Gideon Meiry and Koby Cohen

Gideon Meiry, Ph.D., is Galil Ofek new CTO. He is a multidisciplinary scientist and entrepreneur with  a long track record and vast experience in leading multidisciplinary teams, inventing and managing intellectual property, managing R&D from concept to product, executing regulatory and reimbursement strategies, fundraising and marketing. Gideon serves also as a technology transfer advisor to the Galil Medical Center. Gideon holds a PhD degree in Physiology and Biophysics from the Faculty of Medicine, Technion, Israel Institute of Technology.

Koby Cohen, Ph.D. is our new CTO for pharma and biotechnology. He is a life science professional with extensive experience in drug development, project scouting and evaluation.  Before joining Galil Ofek, Kobi held a director position at the Global Innovative R&D at Teva Pharmaceutical Industries. Kobi was responsible for identifying and pursuing collaboration, licensing and partnership with biotech companies and academic institutions worldwide. Kobi completed his Ph.D. and post doc fellowship at the Tel Aviv University and the Weizmann Institute of Science.
Thank You!

We would like to thank our former CTO Arnin Cohen, for his excellent contribution to Galil Ofek.

Thanks to Arnin Cohen

We would like to thank our former CTO Arnin Cohen, for his excellent contribution to Galil Ofek.

May 2018

 

Mor Research Applications joins Galil Ofek

Mor Research Applications is the technology transfer unit of Clalit Health Services, the largest HMO in Israel, Mor’s commercialization portfolio comprises over 100 different projects and companies at various stages of development.
The intellectual property is conceived and developed by professionals working at Clalit’s 14 hospitals and around 2000 clinics across the country. Clalit has one of the largest structured clinical databases in the world, with data of millions of patients aggregated for over two decades.

Galil Ofek completes a year of activity

Galil Ofek is proud to conclude the second year of operation as a technology incubator with the following achievements:

  • Five new companies have been incubated and four other have been approved by the Innovation Authority and plan to start operating soon.
  • EndoStream has successfully accomplished the final milestones ahead of time and concluded its incubation period.
  • Over 8 million NIS have been raised by Galil’s portfolio companies.

Liora Sklair Tavron leaves Galil Ofek

We would like to thank our former CTO Pharma, Liora Sklair Tavron, who is leaving us for a senior position in an exciting startup. Good luck!

Font Resize